Novavax's Prototype Vaccine Shows Broad Immune Responses Incl. Against Omicron And Other Variants

Novavax Inc.'s (NVAX) prototype vaccine (NVX-CoV2373) demonstrated broad immune responses including against Omicron and other circulating variants. Pre-clinical data demonstrated that boosting with the company's Omicron or prototype vaccine induced immune response against Omicron variants, including BA.4/5, the company said in a statement.

The company said it participated in the U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee's or VRBPAC meeting which resulted in a 19-2 vote to recommend inclusion of a SARS-CoV-2 Omicron component for COVID-19 booster vaccines in the U.S. beginning this fall.

During the meeting, Novavax highlighted data showing that the structural features of Novavax' protein-based COVID-19 vaccine, enhanced by the Matrix-M adjuvant, displayed epitopes across both the original strain and emerging variants, contributing to the generation of broadly cross-reacting antibodies.

Additional data from Phase 2 and Phase 3 trials, as well as in vitro data on neutralizing antibodies and receptor inhibition from trial participants, showed cross-reactivity with all variants tested, particularly following booster doses.

According to the company, preclinical trial data showed that boosting with either the prototype (NVX-CoV2373), Omicron BA.1 (NVX-CoV2515), or bivalent vaccine generated antibody levels that were consistent with dosing regimens in the Phase 3 clinical trials. While boosting with the prototype covers all strains, providing an Omicron booster enhances immunity to related Omicron sub-variants.

Boosting with a bivalent vaccine containing prototype and Omicron BA.1 showed no advantages in any of the responses compared to boosting with BA.1 alone.

A clinical trial is ongoing with results anticipated in September and product availability expected in fourth quarter.

Novavax submitted a request to the FDA for Emergency Use Authorization in January 2022. The VRBPAC Committee voted 21 to 0 with one abstention on June 7, 2022, to recommend that the FDA grant Emergency Use Authorization for NVX-CoV2373 for individuals aged 18 years and over.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ride-hailing company Lyft announced its foray into the media and advertisement business with the launch of Lyft Media as part of its vision to build the world's largest transportation media network. Lyft Media has built a suite of new products to allow advertisers to engage with Lyft's growing audience throughout their transportation journeys. Sysco Corp. (SYY) Tuesday reported a more than a three-times surge in fourth-quarter earnings, supported by 17.5 percent growth in sales. The company projects fiscal 2023 adjusted earnings to grow. Earnings for the quarter spiked to $509.99 million from $151.09 million last year. On a per share basis,... Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22.
Follow RTT